Semaglutide vs Retatrutide.

Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist, an acylated, structurally modified analog of the native incretin hormone GLP-1, engineered for once-weekly (injectable) or daily (oral) dosing through albumin binding and resistance to DPP-4 degradation. It is a fully approved prescription medicine marketed as Ozempic and Rybelsus (type 2 diabetes) and Wegovy (chronic weight management and, more recently, cardiovascular risk reduction). It is one of the most extensively studied peptide therapeutics in modern medicine, with large dedicated cardiovascular- and liver-outcome trials.

Retatrutide (development code LY3437943) is an investigational once-weekly injectable peptide developed by Eli Lilly for the treatment of obesity and related cardiometabolic disease. It is a single synthetic peptide engineered to act as a "triple G" agonist, simultaneously stimulating three nutrient-hormone receptors: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. This distinguishes it from the single agonist semaglutide (GLP-1) and the dual agonist tirzepatide (GIP/GLP-1), both already approved.

Semaglutide binds and activates the GLP-1 receptor, a G-protein-coupled receptor expressed on pancreatic beta cells, the central nervous system, and elsewhere. In the pancreas it augments glucose-dependent insulin secretion and suppresses glucagon, lowering blood glucose with low intrinsic hypoglycemia risk because the effect is glucose-dependent. Centrally, it acts on hypothalamic and hindbrain appetite circuits to increase satiety and reduce food intake, and it slows gastric emptying; the combination drives weight loss. The molecule's C18 fatty-diacid side chain promotes albumin binding, which extends its half-life to roughly a week and underlies once-weekly dosing.

Retatrutide is a balanced agonist at three receptors, each contributing a distinct metabolic effect. GLP-1 receptor agonism enhances glucose-dependent insulin secretion, slows gastric emptying, and acts centrally to reduce appetite and food intake. GIP receptor agonism further modulates insulin response and appears to improve nutrient handling and tolerability. The defining addition is glucagon receptor agonism, which raises hepatic glucose output and, importantly, increases energy expenditure and promotes hepatic lipid oxidation/mobilization. The combination is intended to layer glucagon-driven increases in energy expenditure and reductions in liver fat on top of the appetite suppression and glycemic benefits of incretin (GLP-1/GIP) signaling. Because glucagon agonism can raise hepatic glucose production and resting heart rate, the receptor balance and dose are designed to keep net effects metabolically favorable.

Human evidence is exceptionally strong and trial-backed rather than preclinical. The STEP 1 randomized trial (NEJM 2021, PMID 33567185) showed substantial, clinically meaningful weight loss versus placebo in adults with overweight/obesity without diabetes. SUSTAIN-6 (NEJM 2016, PMID 27633186) demonstrated reduced major adverse cardiovascular events in type 2 diabetes, and SELECT (NEJM 2023, PMID 37952131) showed a significant reduction in cardiovascular death, myocardial infarction, or stroke in people with obesity and established cardiovascular disease but without diabetes. The phase 3 ESSENCE trial (NEJM 2025, PMID 40305708) reported improvement in metabolic dysfunction-associated steatohepatitis (MASH). A documented limitation: the STEP 1 extension (Diabetes Obes Metab 2022, PMID 35441470) showed substantial weight regain after discontinuation, indicating benefits depend on continued use.

Human evidence comes from a completed Phase 2 program and emerging Phase 3 data, so this is no longer animal-only, though long-term outcome and safety data remain immature. In the 48-week Phase 2 obesity trial (Jastreboff et al., NEJM 2023), adults with obesity/overweight without diabetes had least-squares mean weight reductions of roughly -17.1%, -22.8%, and -24.2% across higher dose groups versus -2.1% with placebo. A parallel Phase 2 trial in type 2 diabetes (Rosenstock et al., Lancet 2023) showed substantial reductions in HbA1c and body weight. A Phase 2a trial in metabolic dysfunction-associated steatotic liver disease (Nature Medicine 2024) reported large relative reductions in liver fat, with the majority of higher-dose participants reaching liver fat below the steatosis threshold. In May 2026 Lilly reported topline Phase 3 results (TRIUMPH-1, ~2,339 adults), with the highest dose producing about 28.3% mean weight loss at 80 weeks; full peer-reviewed Phase 3 publications and the broader TRIUMPH cardiovascular/diabetes outcome trials were still pending at that time.

The most common documented adverse effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation, typically most pronounced early in treatment. Labeled warnings include a boxed warning for thyroid C-cell tumors based on rodent data (clinical relevance in humans remains uncertain), plus risks of pancreatitis, gallbladder disease, acute kidney injury from dehydration, and diabetic retinopathy complications in susceptible patients. Reduced lean mass alongside fat loss, and weight regain after stopping, are recognized. Use of unregulated, compounded, or research-grade "semaglutide" sold outside the approved supply chain carries additional, poorly characterized risks of contamination, mislabeling, and dosing errors.

In trials the most common adverse events were gastrointestinal (nausea, vomiting, diarrhea, constipation), dose-related, mostly mild to moderate, and concentrated during dose escalation; using a lower starting dose partially mitigated them. A mechanistically important signal is a dose-dependent increase in heart rate, which in the Phase 2 obesity trial peaked around 24 weeks before declining; glucagon receptor agonism also raises hepatic glucose output, requiring monitoring. Phase 3 topline data showed dose-dependent discontinuation due to adverse events. Because retatrutide is investigational, its long-term safety, cardiovascular outcomes, and effects in broad real-world populations are not yet established. Compounded, "research-use-only," or gray-market retatrutide is not quality-controlled and carries additional, unquantified risks.

Semaglutide is FDA-approved (not investigational): Ozempic and Rybelsus for type 2 diabetes with cardiovascular risk-reduction indications, and Wegovy for chronic weight management and for cardiovascular risk reduction in adults with cardiovascular disease and overweight/obesity. Oral semaglutide for chronic weight management and a MASH indication are the most recent regulatory developments.

As of mid-2026 retatrutide is investigational and not approved by the FDA, EMA, MHRA, or any other regulator for any indication; it remains in Phase 3 development (the TRIUMPH program) by Eli Lilly. It is not a dietary supplement and any product sold as "research-use-only" retatrutide is unapproved.